- Home
- MAZE vs LTBR Comparison
MAZE vs LTBR Comparison
Compare MAZE & LTBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAZE
- LTBR
- Stock Information
- Founded
- MAZE 2018
- LTBR 1992
- Country
- MAZE United States
- LTBR United States
- Employees
- MAZE N/A
- LTBR N/A
- Industry
- MAZE
- LTBR Professional Services
- Sector
- MAZE
- LTBR Consumer Discretionary
- Exchange
- MAZE NYSE
- LTBR Nasdaq
- Market Cap
- MAZE 367.0M
- LTBR 326.6M
- IPO Year
- MAZE 2025
- LTBR N/A
- Fundamental
- Price
- MAZE $11.74
- LTBR $13.81
- Analyst Decision
- MAZE Strong Buy
- LTBR
- Analyst Count
- MAZE 3
- LTBR 0
- Target Price
- MAZE $25.67
- LTBR N/A
- AVG Volume (30 Days)
- MAZE 100.1K
- LTBR 2.2M
- Earning Date
- MAZE 08-14-2025
- LTBR 07-30-2025
- Dividend Yield
- MAZE N/A
- LTBR N/A
- EPS Growth
- MAZE N/A
- LTBR N/A
- EPS
- MAZE 0.34
- LTBR N/A
- Revenue
- MAZE $167,500,000.00
- LTBR N/A
- Revenue This Year
- MAZE N/A
- LTBR N/A
- Revenue Next Year
- MAZE N/A
- LTBR N/A
- P/E Ratio
- MAZE $30.79
- LTBR N/A
- Revenue Growth
- MAZE N/A
- LTBR N/A
- 52 Week Low
- MAZE $6.71
- LTBR $2.24
- 52 Week High
- MAZE $17.00
- LTBR $17.70
- Technical
- Relative Strength Index (RSI)
- MAZE N/A
- LTBR 52.94
- Support Level
- MAZE N/A
- LTBR $12.01
- Resistance Level
- MAZE N/A
- LTBR $14.71
- Average True Range (ATR)
- MAZE 0.00
- LTBR 1.22
- MACD
- MAZE 0.00
- LTBR -0.21
- Stochastic Oscillator
- MAZE 0.00
- LTBR 38.15
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
About LTBR Lightbridge Corporation
Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.